Lung Non-Small Cell Carcinoma

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

31 drugs in development·8 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(17)

Drug	Company
capmatinib	GH Research PLC (GHRS)
cemiplimab	GH Research PLC (GHRS)
Cemiplimab	ENANTA PHARMACEUTICALS INC (ENTA)
Ceralasertib	ENANTA PHARMACEUTICALS INC (ENTA)
Ceralasertib	Crinetics Pharmaceuticals, Inc. (CRNX)
Cetuximab Sarotalocan Sodium	FATE THERAPEUTICS INC (FATE)
chemotherapy	GH Research PLC (GHRS)
chemotherapy	GH Research PLC (GHRS)
Ensartinib	ENANTA PHARMACEUTICALS INC (ENTA)
Ensartinib	Merus N.V. (MRUS)
Erlotinib	Amneal Pharmaceuticals, Inc. (AMRX)
Etoposide	ADMA BIOLOGICS, INC. (ADMA)
Immune Checkpoint Inhibitor	Merus N.V. (MRUS)
osimertinib	GH Research PLC (GHRS)
Pemetrexed Disodium	ADMA BIOLOGICS, INC. (ADMA)
ramucirumab	GH Research PLC (GHRS)
tepotinib	GH Research PLC (GHRS)

Phase 2(6)

Drug	Company
Cemiplimab	Assertio Holdings, Inc. (ASRT)
Cemiplimab	FATE THERAPEUTICS INC (FATE)
Crizotinib	Amneal Pharmaceuticals, Inc. (AMRX)
Diclofenac Potassium	ENANTA PHARMACEUTICALS INC (ENTA)
Ensartinib	ADMA BIOLOGICS, INC. (ADMA)
Pemetrexed	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 1(2)

Drug	Company
Crizotinib	ENANTA PHARMACEUTICALS INC (ENTA)
Pemetrexed	ADMA BIOLOGICS, INC. (ADMA)

N/A(4)

Drug	Company
Crizotinib	Crinetics Pharmaceuticals, Inc. (CRNX)
Erlotinib	Crinetics Pharmaceuticals, Inc. (CRNX)
Pemetrexed Disodium	Crinetics Pharmaceuticals, Inc. (CRNX)
Pemetrexed Disodium	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 2/Phase 3(1)

Drug	Company
nogapendekin alfa	GH Research PLC (GHRS)

Phase 4(1)

Drug	Company
Diclofenac Potassium	Assertio Holdings, Inc. (ASRT)

BioSniper tracks 31 drugs in development for Lung Non-Small Cell Carcinoma across 8 companies.

There are 9 clinical trials targeting Lung Non-Small Cell Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.